Journals / Meme Sağlığı Dergisi / 2010 / Cilt: 6 - Sayı: 3

The factors effecting mortality in stage 1 breast cancer

Evre 1 meme kanserli hastalarda mortaliteyi etkileyen faktörler

Pages
107–112
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: This study showed that tumor size, being under age of 35 years, progesterone receptor negativity and progesteron reseptor negativity with estrogen reseptor positivity were the factors related with the stage 1 breast cancer mortality.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The incidence of stage 1 breast cancer has been increasing with screening mammography and awareness of breast cancer.
📊
Key Findings & Data:The aim of this study was to examine the factors effecting the mortality in patients with stage 1 breast cancer.
💡
Conclusion & Impact:Discussion: This study showed that tumor size, being under age of 35 years, progesterone receptor negativity and progesteron reseptor negativity with estrogen reseptor positivity were the factors related with the stage 1 breast cancer mortality.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: The incidence of stage 1 breast cancer has been increasing with screening mammography and awareness of breast cancer. However, some patients with early stage breast cancer have been died due to the recurrence of disease. The aim of this study was to examine the factors effecting the mortality in patients with stage 1 breast cancer. Materials and Methods: 250 stage 1 breast cancer patients treated and followed at Istanbul University, Istanbul Medical Faculty, Department of General Surgery, The Breast Unit between January 1995 and December 2008 were eligible and included in this study. Demographic and pathological data were collected retrospectively. Twenty-five patients of them had died during the follow up period due to tumor recurrence and the factors affecting the mortality in stage 1 breast cancer were examined. Results: The median age of pateints was 53 (27&#8211;81) years, median follow up time was 35 months (8-158), 5 year survival was 87,1%. Twenty-five patients had died during follow up period [Median follow up time was 60 months (24&#8211; 150)]. The relation between mortality and age, tumor size, histopathology, tumor localisation, lymphovascular invasion, estrogen, progesterone and Her 2 receptor status and histologic grade was examined. Young age (<35 years old, p=0.026), tumor size more than 15 mm (p=0.002) and progesterone receptor negativity (p=0.017) were the only factors affecting the mortality. Discussion: This study showed that tumor size, being under age of 35 years, progesterone receptor negativity and progesteron reseptor negativity with estrogen reseptor positivity were the factors related with the stage 1 breast cancer mortality.

Özet

Giriş: Tarama mamografisi ve meme kanseri farkındalığının artması, evre I meme kanseri (T1N0M0) görülme sıklığını artırmaktadır. Ancak, erken tanıya rağmen, bazı hastalar meme kanserinin nüksü sonucu kaybedilmektedir. Bu çalışmanın amacı, evre I meme kanseri tanısı ile tedavi ve takip edilen hastalarda mortaliteyi etkileyen faktörleri araştırmaktır. Yöntem ve Gereçler: Ocak 1995-Aralık 2008 tarihleri arasında İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Meme Hastalıkları Ünitesi'nde, evre I meme kanseri tanısı ile ameliyat edilen 250 hastaya ait demografik ve patolojik özellikler retrospektif olarak incelendi. Takip süresi içerisinde meme kanserinin nüksü sonucu kaybedilen 25 hasta ile hastalıksız olarak yaşayan 225 hasta karşılaştırılarak, mortalite üzerinde etkili faktörler araştırıldı. Bulgular: Hastaların ortanca yaşı 53 (27–81), ortanca takip süresi 35 ay (8- 158), 5 yıllık sağkalım oranı ise %87,1'dir. Takip sırasında 25 (%10) hasta, hastalığa bağlı nedenlerle kaybedildi [Ortanca takip süresi 60 ay (24–150)]. Evre 1 meme kanseri (T1N0M0) olup kaybedilenler ile hastalıksız yaşayan hastalar yaş, tümör çapı, histopatolojik tip, tümör lokalizasyonu, lenfovasküler invazyon varlığı, östrojen, progesteron ve Her 2 reseptör durumu ve histolojik grad yönünden karşılaştırıldığında, 35 yaş altında olmak (p=0.026) ve progesteron reseptör negatifliği (p=0.017) mortaliteyi etkileyen faktörler olarak tespit edildi. Tartışma: Bu çalışmanın sonuçları, evre I meme kanseri olan kadınlarda, tümör çapı, yaş (<35) ve progesteron reseptörü negatifliğinin mortaliteyi arttırıcı bağımsız faktörler olduğunu göstermekle beraber, progesteron reseptörü negatifliğinin-östrojen reseptörü pozitifliği ile birlikte olması mortalitede anlamlı bir artışa neden olmaktadır.

🔖

Cite This Article

BOZDOĞAN, A., ÖZÇINAR, B., GÜRDAL, S. Ö., MÜSLÜMANOĞLU, M., İĞCİ, A., KEÇER, M., ÖZMEN, V. (2010). The factors effecting mortality in stage 1 breast cancer. Meme Sağlığı Dergisi, Cilt: 6 - Sayı: 3, 107–112. https://ajindex.com/articles/278173

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Özmen V, Fidaner C, Aksaz E, Bayol Ü, Dede İ, Göker E, Güllüoğlu M. B, I Abdurrahman, Topal U, Uhri M, Utkan Z, Zengin N, Tuncer M. Türkiye'de meme kanseri erken tanı ve tarama programlarının hazırlanması “Sağlık Bakanlığı meme kanseri erken tanı ve tarama alt kurulu raporu”. Meme Sağlığı Dergisi 2009,3: 125–134
  2. Koç Z, Sağlam Z, Kadınların meme kanseri, koruyucu önlemler ve kendi kendine meme muayenesi ile ilgili bilgi ve uygulamalarının belirlenmesi ve eğitimin etkinliği, Meme Sağlığı Dergisi 2009,1:25-33
  3. TC Sağlık Bakanlığı, Kadınlarda en çok görülen on kanser türü, Kanserle Savaş Dairesi Başkanlığı, 2005 Yılı Türkiye Kanser İstatistikleri http://www.saglikgov.tr.Ulaşım tarihi: 27.11. 2009
  4. Duffy SW, Tabar L, Fagerberg G, Gad A, Gröntoft O, South MC, Day NE. Breast screening, prognostic factors and survival-results from the Swedish two county study. Br J Cancer 1991;64:1133–1138.( PMID: 1764377
  5. Tabar L, Fagerberg G, Day NE, Duffy SW, Kitchin RM. Breast cancer treatment and natural history: new insights from the results of screening. Lancet 1992;339:412–414.( PMID: 1346670
  6. Anderson TJ, Lamb J, Donnan P, Alexander FE, Huggins A, Muir BB, Kirkpatrick AE, Chetty U, Hepburn W, Smith A. Comparative pathology of breast cancer in a randomized trial of screening. Br J Cancer 1991;64:108–113.( PMID: 1854609
  7. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer. 1999;85: 2183-2189.( PMID: 10326696
  8. Fisher ER, Redmond C, Fisher B, Bass G Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer 1990;65:2121-2128.( PMID: 2328478
  9. Chin SK, Speers CH, Bryce CJ. Ten-year outcomes in a populationbased cohort of node-negative, lymphatic, and vascular invasionnegative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22:1630-1637. (PMID: 15117985
  10. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 1992;70(6 Suppl):1775-1781.( PMID: 1355403
  11. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;2:3357-3365. (PMID: 12847142
  12. Loprinzi CL, Thome SD. Understanding the utility of adju